Overview
Merit Medical Q3 revenue grows 13% yr/yr, beating analyst expectations
Adjusted EPS for Q3 beats consensus, rising 6.7% yr/yr
Company raises 2025 revenue and non-GAAP EPS guidance, citing strong Q3 results
Outlook
Merit Medical raises 2025 revenue guidance to $1.502 bln - $1.515 bln
Company updates 2025 non-GAAP EPS guidance to $3.66 - $3.79
Merit Medical expects stable constant currency growth and improving profitability
Result Drivers
CARDIAC INTERVENTION GROWTH - Cardiac Intervention segment revenue increased by 29.3%, contributing significantly to overall revenue growth
OPERATING MARGIN IMPROVEMENT - Non-GAAP operating margin improved to 19.7% from 19.2% in the prior year period
CEO COMMENTARY - CEO Martha G. Aronson attributed strong Q3 performance to effective execution and stable growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $384.20 mln | $371.90 mln (11 Analysts) |
Q3 Adjusted EPS | Beat | $0.92 | $0.83 (10 Analysts) |
Q3 EPS | $0.46 | ||
Q3 Adjusted Net Income | Beat | $54.90 mln | $50 mln (9 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Merit Medical Systems Inc is $103.50, about 21.4% above its October 29 closing price of $81.39
Press Release: ID:nGNX8QL9gF
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)